Prev Close | 92.69 |
Day Low/High | 92.31 / 93.16 |
52 Wk Low/High | 75.96 / 115.61 |
Avg Volume | 1.34M |
Prev Close | 92.69 |
Day Low/High | 92.31 / 93.16 |
52 Wk Low/High | 75.96 / 115.61 |
Avg Volume | 1.34M |
Exchange | NASDAQ |
Shares Outstanding | 219.01M |
Market Cap | 20.30B |
EPS | 6.70 |
P/E Ratio | 14.60 |
Div & Yield | 2.40 (2.08%) |
A special in-depth report.
NTRS is setting up well for a catch-up rally.
Five examples show how post-earnings price patterns provide valuable additional information.
Strong capital ratios, solid loan portfolios and attractive valuations argue for higher prices for financials.
The demand for green bonds is not just taking root, it is blossoming, says Northern Trust.
The positive jobs data reminds me of WWE superstar Dwayne 'The Rock' Johnson: 'Can you smell a rate-hike cooking?'
Building a profitable business from scratch is no small feat.
Both financials took hits after their earnings reports but remain solid operators.
The strongest sector right now is benefiting from interest rates talk.
They keep giving out low-cost commercial and industrial loans.
A number of factors have contributed.
Where it began. The rundown: U.S. futures are higher this morning (S&P up 6 handles, Nasdaq up 18 handles). European stocks are climbing, too (by about 0.8%). Nikkei is up 0.88%. Within the Nikkei, all major sub-groups finished in the green. Telecom...
The stock is poised to climb after a lackluster start to 2014.
Northern Trust may soon slow down after Friday's surge -- and, if it does, I'll be selling some.
This impressive move on earnings extends a solid rebound in the shares.
Let's take a look at the overnight and early-morning price action in the major asset classes. The rundown: S&P futures are up 4; Nasdaq futures are up +15; Nikkei is up 2.48% -- Olympic fever (see below, all sectors higher); China Shanghai is up 3.3...
Let's take a peek at overnight and early-morning price action in the major asset classes. Exit light Enter night Take my hand We're off to never never land. -- Metallica, "Enter Sandman" Let's take a peek at overnight and early-morning price action ...
Alnylam Pharmaceuticals upcoming meeting is the next big thing in biotech, says TheStreet Sr. columnist Adam Feuerstein.
ETFs are making huge strides, but they won't kill off individual stockpicking, says Shundrawn Thomas, Head of Northern Trust's FlexShares.
After a weak start, shares are within a dollar of 52-week highs.
Don't fret bank earnings, gold's plunge or the belief that the Fed Chairman has bitten off more bonds than he can chew, Carl Tannenbaum, chief economist at Northern Trust, tells Gregg Greenberg.